Cannabidiol

Related Terms

(-)-4-(3-3,4-Trans-p-menthadien-[1,8]-yl)olivetol, 11-hydroxy-delta-9-THC, abnormal cannabidiol, ageef, ageeve, almindelig hamp (Danish), anashca, asa (Japanese), asanomi, bang (Arabic - Egypt), banji, bhaang (Hindi, Nepali), bhaango (Nepali), bhang (Hindi), blunt, bud, c??amo (Spanish), canapa (Italian), canapa indiana (Italian), canapa indica (Italian), canape (Italian), c?nhamo (Portuguese), Cannabaceae (family), cannabidiol, (-)-cannabidiol, cannabidiol-dimethylheptyl, cannabis, cannabis extracts, Cannabissativa, Cannabissativa subsp. indica, Cannabissativa subsp. sativa, Cannabissativa subsp. spontanea, cannaboid, cares (Nepali), CBD, CBD-DMH, Cesamet?, chanvre (French), chanvre cultiv? (French), chanvre de l'Inde (French), chanvre indien (French), chanvrier (French), charas (Hindi), churras (Hindi), CP 47,497, d? m? (Chinese), da ma cao (Chinese), da ma ren (Chinese), dagga (Afrikaans), delta(9)-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, delta-9-THC-cannabidiol, dope, dronabinol, echter Hanf (German), esrar, Finola?, gaanjaa (Nepali), gaga, gajiimaa (Nepali), ganja (Sanskrit, Hindi, Nepali, Urdu), ganjika (Sanskrit), grass, grifa (Spanish), hach?s (Spanish), hamp (Danish, Norwegian), hampa (Swedish), hampjurt (Icelandic), hamppu (Finnish), Hanf (German), harilik kanep (Estonian), Haschischpflanze (German), hash, hashish, hashish qinnib (Arabic), hemp, hemp ale, hemp flour, Hemp Foods Australia?, Hemp Liquid Gold, hemp nut butter, hemp oil, Hemp Organics, hemp plant, hemp protein powder, hemp seed meal, hemp seed nut butter spread, hemp seed nuts, hemp seed oil, hempseed, hempseed oil, hemp-seeds, hempzels, hennep (Dutch), herbal incense, herbal smoking blends, HU-331, huo ma (Chinese), huo ma cao (Chinese), huo ma ren (medicinal name) (Chinese), Indian hamp, Indian hemp, indiiskaia konoplia (Russian), indische hennep (Dutch), indisk hamp (Danish), industrial hemp, joint, JWH-018, K2, kannabisu (Japanese), kenevir (Turkish), kendir (Turkish), kief, kif (Arabic - Morocco), konop? set? (Czech), konopie (Polish), konopie siewne (Polish), konoplia sornaia (Russian), konoplja (Slovenian), Kultur-Hanf (German), kush, maconha (Portuguese), Manitoba Harvest, mariguana, marihuana, marijuana, Marinol?, Mary Jane, mashinin (Japanese), nabilone, navadna konoplja (Slovenian), Nutiva?, O-1918, Organic Hemp Protein Powder, phytocannabinoids, porkanchaa (Thai), pot, PVL's Certified Organic Protein Powders, qinnib (Arabic), riesen Hanf (German), roasted hemp, Sativex?, sawi, sh?hd?nag (Arabic), shar?neq (Arabic), shelled hempseed, sinsemilla, Spice, taima (Japanese), THC, t?l (Arabic), unika-b, vadkender (Hungarian), vet?si kinder (Hungarian), weed, wild hemp, wilder Hanf (German), ye da ma (Chiense), ye ma (Chinese).

Background

Marijuana, hemp, and cannabis are common names for plants of the genus Cannabis. The term "hemp" is used for Cannabis plants that are grown for nondrug use, such as Cannabis sativa. Cannabis indica has poor fiber quality and is used to make drugs for recreation and medicine. The major differences between the two are appearance and the amount of delta-9-tetrahydrocannabinol (THC), the active ingredient of marijuana.
Cannabis sativa is widely used for recreation. It has been inhaled or taken by mouth to produce a feeling of relaxation or well-being. The plant has been studied as a potential treatment for many conditions, including chronic skin disorders, cancer-related weakness and weight loss, chronic pain, Huntington's disease, sleep disorders, eye disease, multiple sclerosis, and schizophrenia. The most significant benefits have been seen in the treatment of chronic pain and multiple sclerosis. Marijuana may help reduce eye pressure in people who have glaucoma.
The most commonly studied ingredients in marijuana are THC and cannabidiol (CBD). Research has looked at these compounds both alone and in combination. Commercially available products include dronabinol (Marinol?), nabilone (Cesamet?), THC, and CBD (Sativex?).

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *


Marijuana has been studied for the treatment of chronic pain. It has been used in people whose pain did not respond to other drugs such as narcotics. Cannabis-based products like Sativex? are used to treat different types of pain, such as pain from cancer or multiple sclerosis. It is approved in Canada and many parts of Europe. In the United States, it is being studied in people who have cancer-related pain. Other cannabis-based products, such as the U.S. Food and Drug Administration (FDA)-approved dronabinol (Marinol?), are also being studied.

 B


Marijuana has been studied for the treatment of chronic pain. It has been used in people whose pain did not respond to other drugs such as narcotics. Cannabis-based products like Sativex? are used to treat different types of pain, such as pain from cancer or multiple sclerosis. It is approved in Canada and many parts of Europe. In the United States, it is being studied in people who have cancer-related pain. Other cannabis-based products, such as the U.S. Food and Drug Administration (FDA)-approved dronabinol (Marinol?), are also being studied.

 B


Marijuana has been studied for the relief of multiple sclerosis symptoms, such as nerve pain, muscle spasms, and urinary disorders. The active ingredients have effects on the central nervous system and immune cells.

 B


Marijuana has been studied for the relief of multiple sclerosis symptoms, such as nerve pain, muscle spasms, and urinary disorders. The active ingredients have effects on the central nervous system and immune cells.

 B


Current studies show that THC may lack benefit in people who have amyotrophic lateral sclerosis. More research is needed.

 C


Current studies show that THC may lack benefit in people who have amyotrophic lateral sclerosis. More research is needed.

 C


Current studies show that cannabis-based therapy may lack benefit on weight loss and anorexia related to cancer. Early studies suggested that marijuana may improve appetite in people who have cystic fibrosis (mucus buildup in the organs) and AIDS. More research is needed.

 C


Current studies show that cannabis-based therapy may lack benefit on weight loss and anorexia related to cancer. Early studies suggested that marijuana may improve appetite in people who have cystic fibrosis (mucus buildup in the organs) and AIDS. More research is needed.

 C


Hemp seed oil may help reduce symptoms of atopic dermatitis, a chronic skin disorder that causes itchy, scaly rashes. This benefit is believed to come from the fatty acids in hemp seed oil. Further research is needed.

 C


Hemp seed oil may help reduce symptoms of atopic dermatitis, a chronic skin disorder that causes itchy, scaly rashes. This benefit is believed to come from the fatty acids in hemp seed oil. Further research is needed.

 C


Marijuana has been studied for potential benefit in people with acute brain injury. However, more research is needed before conclusions can be made.

 C


Marijuana has been studied for potential benefit in people with acute brain injury. However, more research is needed before conclusions can be made.

 C


Studies suggest that marijuana may help reduce nausea and vomiting in people undergoing chemotherapy. However, it may cause side effects such as sleepiness and changes in mood. One review suggests that marijuana may cause more side effects in children undergoing chemotherapy than other therapies. However, the effect of cannabis alone is unclear, and further research is needed.

 C


Studies suggest that marijuana may help reduce nausea and vomiting in people undergoing chemotherapy. However, it may cause side effects such as sleepiness and changes in mood. One review suggests that marijuana may cause more side effects in children undergoing chemotherapy than other therapies. However, the effect of cannabis alone is unclear, and further research is needed.

 C


Early studies suggest that marijuana may benefit weight gain and behavior in people who have dementia. More research is needed before conclusions can be made.

 C


Early studies suggest that marijuana may benefit weight gain and behavior in people who have dementia. More research is needed before conclusions can be made.

 C


In patients with eating disorders THC had a lack of effect on weight, caloric intake, and psychiatric assessment. Further research is required.

 C


In patients with eating disorders THC had a lack of effect on weight, caloric intake, and psychiatric assessment. Further research is required.

 C


Early studies suggest that marijuana taken with antiseizure drugs may lower seizure risk in people with epilepsy. However, the evidence is limited. More research is needed on whether marijuana may be effective in treating epilepsy.

 C


Early studies suggest that marijuana taken with antiseizure drugs may lower seizure risk in people with epilepsy. However, the evidence is limited. More research is needed on whether marijuana may be effective in treating epilepsy.

 C


People who have glaucoma have high pressure in the eye, which may lead to optic nerve damage and vision loss. Some studies suggest that THC may lower eye pressure, while CBD may lack benefit or actually increase pressure. More research is needed to understand the possible role of marijuana in glaucoma treatment.

 C


People who have glaucoma have high pressure in the eye, which may lead to optic nerve damage and vision loss. Some studies suggest that THC may lower eye pressure, while CBD may lack benefit or actually increase pressure. More research is needed to understand the possible role of marijuana in glaucoma treatment.

 C


Symptoms of Huntington's disease include impaired brain function and jerky body movements. Early research suggests that CBD may lack effect on movement problems caused by Huntington's, although the marijuana-based drug nabilone may have benefits. More studies are needed in this area.

 C


Symptoms of Huntington's disease include impaired brain function and jerky body movements. Early research suggests that CBD may lack effect on movement problems caused by Huntington's, although the marijuana-based drug nabilone may have benefits. More studies are needed in this area.

 C


Marijuana has been studied in the treatment of symptoms of nerve and muscle disorders. Researchers looked for possible benefits on appetite, saliva production, mood, muscle health, and sleep. More research is needed before conclusions can be made.

 C


Marijuana has been studied in the treatment of symptoms of nerve and muscle disorders. Researchers looked for possible benefits on appetite, saliva production, mood, muscle health, and sleep. More research is needed before conclusions can be made.

 C


There is some controversy over the use of marijuana in people who have cancer or other long-term illnesses. It has been studied for increasing appetite, treating stomach problems, improving mood and sleep, and reducing pain. More research is needed before conclusions can be made.

 C


There is some controversy over the use of marijuana in people who have cancer or other long-term illnesses. It has been studied for increasing appetite, treating stomach problems, improving mood and sleep, and reducing pain. More research is needed before conclusions can be made.

 C


Limited research suggests that Sativex? may reduce pain and improve sleep quality in people who have rheumatoid arthritis. More research is needed.

 C


Limited research suggests that Sativex? may reduce pain and improve sleep quality in people who have rheumatoid arthritis. More research is needed.

 C


Early research suggests that CBD may lack effect in people who have schizophrenia. Other research reports that cannabis users may have better brain function than nonusers. However, long-term use of cannabis has been linked to a higher risk of psychiatric problems. These include bipolar disorder, anxiety, suicidal thoughts, depression, delusions, hallucinations, aggression, and lack of motivation or energy. More research is needed.

 C


Early research suggests that CBD may lack effect in people who have schizophrenia. Other research reports that cannabis users may have better brain function than nonusers. However, long-term use of cannabis has been linked to a higher risk of psychiatric problems. These include bipolar disorder, anxiety, suicidal thoughts, depression, delusions, hallucinations, aggression, and lack of motivation or energy. More research is needed.

 C


Limited research suggests that CBD may help people who have problems sleeping. However, more studies are needed before conclusions can be made.

 C


Limited research suggests that CBD may help people who have problems sleeping. However, more studies are needed before conclusions can be made.

 C


Some research reports that marijuana may improve some symptoms of Tourette's syndrome. However, significant benefit over placebo is lacking for tics and other symptoms. More research is needed in this area.

 C


Some research reports that marijuana may improve some symptoms of Tourette's syndrome. However, significant benefit over placebo is lacking for tics and other symptoms. More research is needed in this area.

 C
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (18 years and older)
To treat amyotrophic lateral sclerosis (nerve cell disease), 10 milligrams of THC has been taken by mouth daily for two weeks.
To prevent nausea and vomiting caused by chemotherapy, five milligrams per meter squared of dronabinol (Marinol?) has been taken by mouth 1-3 hours before chemotherapy, then every 2-4 hours after chemotherapy, for a total of 4-6 doses daily. A dose of two milligrams of nabilone has been taken by mouth the night before chemotherapy, 1-3 hours before and after chemotherapy. A dose of 2-3 milligrams of nabilone has been taken by mouth 2-4 times daily. A dose of three milligrams of nabilone has been taken by mouth three times daily as a one-time dose, a four-day duration, and the duration of two cycles of chemotherapy. Cannabinoids have been taken by mouth over a 24-hour period as follows: 1-8 milligrams of nabilone daily as 1-4 milligrams daily, one milligram 3-5 times daily, or two milligrams 2-4 times daily or 24-50 milligrams per meter squared of dronabinol daily as 10 milligrams per meter squared 4-5 times daily, 12 milligrams per meter squared twice daily, or 15 milligrams twice daily. A dose of one milligram of nabilone has been taken by mouth 8-12 hours before chemotherapy, followed by 0.5-2 milligrams of nabilone 2-3 times daily after chemotherapy, depending on body weight. A dose of 10 milligrams per meter squared of THC has been taken by mouth two hours before and four, eight, 16, and 24 hours after chemotherapy. Cannabinoids have been injected into the muscle over the course of 24 hours in the form of 0.5-1 milligrams of levonantradol three times daily.
To treat atopic dermatitis (itchy, scaly skin rashes), hemp seed oil has been taken by mouth for 20 weeks.
To increase appetite in people with cancer, 2.5 milligrams of THC has been taken by mouth with or without one milligram of CBD for six weeks.
To treat chronic pain, cannabinoids have been taken by mouth in the form of capsules or sprayed into the mouth as THC, benzopyranoperidine (BPP), cannabidiol (CBD), nabilone, dronabinol, or synthetic nitrogen THC analogs (NIB), with doses of 2.5-20 milligrams for an average of 25 days. Cannabis-based medicines have been used for 1-6 weeks. Ajulemic acid has been used for one week. Doses of nabilone of 0.25-2 milligrams have been used daily for 4-6 weeks. Doses of smoked cannabis of 1-9.4 percent have been used for six hours to 14 days. Cannabis has been smoked 3-4 times daily for five days. Doses of dronabinol of 10-20 milligrams have been used daily for six hours to six weeks. In people with cancer, 5-20 milligrams of delta-9-THC has been taken by mouth daily, as have the following doses: 2-8 milligrams of nabilone by mouth daily; 0.25-1 milligram of nabilone by mouth daily for four weeks; 1-2 milligrams of nabilone twice daily for a year; 1-2 milligrams of nabilone twice at an eight-hour interval; and 0.5 milligrams of nabilone twice daily for seven days, followed by two milligrams daily for three weeks. A dose of 0.5-1 milligrams of nabilone has been taken twice daily. A dose of 10 milligrams of THC has been taken by mouth, increasing to a maximum tolerated dose for six weeks. A mouth sprayhas been used in divided doses of 2.5-120 milligrams for two weeks. Doses of Sativex? have been sprayed into the mouth, up to 48 sprays daily, for 1-2 weeks, then 10-15 sprays daily, or 4-8 sprays, with eight being the maximum one-time dose or within a three-hour period.
To improve appetite in people with cystic fibrosis (mucus buildup in the organs), a dose of 2.5 milligrams of dronabinol has been taken by mouth, increasing to a maximum of 10 milligrams daily for 1-6 months.
To treat dementia, 2.5 milligrams of dronabinol has been taken by mouth twice daily for six weeks.
To treat eating disorders, 7.5-30 milligrams of THC has been taken by mouth daily for four weeks.
To treat epilepsy, 200-300 milligrams of CBD has been taken by mouth daily for up to 4.5 months.
To improve fatty acid status, hemp seed oil has been taken by mouth.
To treat movement problems caused by Huntington's disease, 1-2 milligrams of nabilone has been taken by mouth daily for five weeks. A dose of 10 milligrams per kilogram of CBD has been taken by mouth daily for six weeks.
To treat sleep disorders, 40-160 milligrams of CBD has been taken by mouth.
To treat multiple sclerosis symptoms, 2.5 milligrams of dronabinol (Marinol?) has been taken by mouth daily, increasing to a maximum of 10 milligrams daily for three weeks. A dose of 15-30 milligrams of cannabis extract capsules has been taken by mouth in five-milligram increments, based on tolerance, for 14 days. Cannabis extracts, including Cannador?, have been taken by mouth for 2-4 weeks. Cannabis plant extracts containing 2.5-120 milligrams of a THC-CBD combination have been taken by mouth daily for 2-15 weeks. A mouth spray (Sativex?, containing 2.7 milligrams of THC and 2.5 milligrams of CBD) has been used at a dose of 2.5-120 milligrams in divided doses for up to eight weeks. Eight sprays within any three hours, up to 48 sprays in a 24-hour period, have been used. Sativex? has been sprayed into the mouth for 6-14 weeks.
As a nutritional supplement, 15-30 milliliters of hemp oil has been taken by mouth daily.
To treat schizophrenia, 40-1,280 milligrams of CBD has been taken by mouth daily for up to four weeks.
To treat Tourette's syndrome, gelatin capsules containing 2.5-10 milligrams of THC have been taken by mouth as a single dose. A dose of 2.5 milligrams of THC has been taken by mouth daily, increasing to 10 milligrams daily in 2.5-milligram intervals over a four-day time period for six weeks.
To treat rheumatoid arthritis, up to six sprays of Sativex? have been used once daily 30 minutes before bed for five weeks.
To treat glaucoma (increased eye pressure), a single dose of five milligrams of THC has been placed under the tongue. A dose of 20-40 milligrams of CBD has been placed under the tongue as a single dose; however, 40 milligrams appeared to increase eye pressure.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Marijuana may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants (blood thinners) such as warfarin (Coumadin?) or heparin, antiplatelet drugs such as clopidogrel (Plavix?), and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin?, Advil?) or naproxen (Naprosyn?, Aleve?).
Marijuana may affect blood sugar levels. Caution is advised when using medications that may also affect blood sugar. People taking drugs for diabetes by mouth or insulin should be monitored closely by a qualified healthcare professional, including a pharmacist. Medication adjustments may be necessary.
Marijuana may cause low blood pressure. Caution is advised in people taking drugs that lower blood pressure.
Marijuana may interfere with the way the body processes certain drugs using the liver's cytochrome P450 enzyme system. As a result, the levels of these drugs may be increased in the blood and may cause increased effects or potentially serious adverse reactions. People using any medications should check the package insert and speak with a qualified healthcare professional, including a pharmacist, about possible interactions.
Marijuana may increase the amount of drowsiness caused by some drugs. Examples include benzodiazepines such as lorazepam (Ativan?) or diazepam (Valium?), barbiturates such as phenobarbital, narcotics such as codeine, some antidepressants, and alcohol. Caution is advised while driving or operating machinery.
Marijuana may also interact with agents that may affect blood vessel width, agents that may affect the immune system, agents that may be toxic to the liver, agents that may improve breathing or treat lung disorders, agents that may increase appetite, agents that may treat heart disorders, agents that may treat nausea or vomiting, agents that may treat nervous system disorders, agents that may treat psychiatric disorders, agents that may treat retrovirus infections (HIV), agents that may treat skin disorders, agents that may treat stomach disorders, anabolic steroids, anticancer agents, antipyrine, antiseizure agents, bromo-dragonFLY, cannabinoid CB1 receptor antagonists, central nervous system depressants, cocaine, corticosteroids, dopamine antagonists, ecstasy, estrogens, fertility agents, hormonal agents, nicotine, nonsteroidal anti-inflammatory agents, opioid receptor antagonists, pain relievers, p-glycoprotein-regulated agents, prochlorperazine, sedatives, and synthetic cannabinoids.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Armstrong MJ and Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 8-7-2012;79(6):597-603.
Asbridge M, Hayden JA, and Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
Baldinger R, Katzberg HD, and Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane.Database.Syst.Rev. 2012;4:CD004157.
Beaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann.Clin.Psychiatry 2012;24(1):38-55.
Carbuto M, Sewell RA, Williams A, et al. The safety of studies with intravenous Delta(9)-tetrahydrocannabinol in humans, with case histories. Psychopharmacology (Berl) 2012;219(3):885-896.
Gunderson EW, Haughey HM, Ait-Daoud N, et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am.J.Addict. 2012;21(4):320-326.
Henggeler SW, McCart MR, Cunningham PB, et al. Enhancing the effectiveness of juvenile drug courts by integrating evidence-based practices. J.Consult Clin.Psychol. 2012;80(2):264-275.
Hjorthoj CR, Hjorthoj AR, and Nordentoft M. Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances--systematic review and meta-analysis. Addict.Behav. 2012;37(3):225-233.
Large MM, Smith G, Sara G, et al. Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings. Int.J.Methods Psychiatr.Res. 2012;21(2):134-148.
Li MC, Brady JE, DiMaggio CJ, et al. Marijuana use and motor vehicle crashes. Epidemiol.Rev. 2012;34(1):65-72.
Ramo DE, Liu H, and Prochaska JJ. Tobacco and marijuana use among adolescents and young adults: a systematic review of their co-use. Clin.Psychol.Rev. 2012;32(2):105-121.
Richards BL, Whittle SL, and Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane.Database.Syst.Rev. 2012;1:CD008921.
Thornton LK, Baker AL, Lewin TJ, et al. Reasons for substance use among people with mental disorders. Addict.Behav. 2012;37(4):427-434.
van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr.Drug Abuse Rev. 2012;5(1):3-31.
Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr.Bull. 2012;38(2):316-330.